Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy

Am J Hematol. 2023 Feb;98(2):361-364. doi: 10.1002/ajh.26783. Epub 2022 Dec 1.

Authors

Ertugrul Bayram¹, Umur Anil Pehlivan², David C Fajgenbaum³, Semra Paydas¹

Affiliations

¹ Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey.
² Department of Radiology, Başkent University Adana Dr. Turgut Noyan Application and Research Center Department of Radiology, Adana, Turkey.
³ Center for Cytokine Storm Treatment & Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

No abstract available

Publication types

Case Reports

MeSH terms

Castleman Disease* / drug therapy
Humans
Sirolimus / therapeutic use

Substances

Sirolimus

Supplementary concepts

Multi-centric Castleman's Disease

Grants and funding